All In Biotech

Drug Trial Radar · NCT04957550

To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of SHR0302 in Active Psoriatic Arthritis Subjects

Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 418 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

418

Actual

Start

Aug 30, 2021

Primary completion

Dec 13, 2026

Study completion Dec 13, 2026

Sponsor

Sponsor type
Industry
First posted
Jul 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase 3 study,to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with active psoriatic arthritis.

Conditions

  • Psoriatic Arthritis

Interventions

  • SHR0302 tablets、PlaceboDrug

    SHR0302 tablets dose 1 for 48 weeks

  • SHR0302 tablets、PlaceboDrug

    SHR0302 tablets dose 2 for 48 weeks

  • PlaceboDrug

    SHR0302 tablets blank preparation for 24 weeks then SHR0302 tablets dose 1/dose 2 for 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ACR20 response rate at week 24Time frame: Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.